Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
University of Ottawa
$25,000.00
Role of the gut microbiome in intestinal barrier function
FY 2018-19
Summary
The intestine is home to a large community of microbes, referred to as the gut microbiome. This community plays a key role in nutrition and digestion. However, as we learn more about the gut microbiome, we are discovering that it affects many different aspects of human health that extend beyond the gut.
The gut microbiome is altered in many diseases, but its exact role in disease development is often difficult to determine. Recent studies suggest that the gut bacteria can even affect diseases outside the intestinal tract, by altering the gut barrier. In healthy humans, the intestinal lining is a selective barrier that allows beneficial substances like nutrients and vitamins to pass from the gut into the bloodstream while keeping out harmful substances like toxins. If the intestinal lining is damaged, these harmful substances may enter the bloodstream and damage distant organs.
Two diseases where patients have an impaired gut barrier are chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD). In CKD, kidney function gradually declines until the patient needs dialysis and eventually a kidney transplant. In NAFLD, the liver accumulates fat cells, which for some people leads to severe liver damage that requires a liver transplantation. Although studies suggest that the microbiome can affect the gut barrier, it has not yet been proven that gut bacteria directly impair the gut barrier in CKD and NAFLD.
Our project will test whether the damaged gut barrier seen in CKD and NAFLD is caused by changes in the gut microbiome. We will identify potentially important bacterial species by determining which bacteria show similar changes in both CKD and NAFLD. This could lead to the development of new therapeutic strategies that target gut bacteria rather than the diseased organs. New therapies that decrease the need for dialysis and organ transplantation would greatly improve quality of life while reducing costs for the Canadian healthcare system.
Department
Program
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
399115
Name
Stintzi Alain
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Role of the gut microbiome in intestinal barrier function
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Chronic Kidney Disease; Intestinal Barrier; Metagenomic; Metaproteomic; Microbiome; Non-Alcoholic Fatty Liver Disease; Pilot Clinical Trial; Therapeutic Approach
Abstract
The intestine is home to a large community of microbes, referred to as the gut microbiome. This community plays a key role in nutrition and digestion. However, as we learn more about the gut microbiome, we are discovering that it affects many different aspects of human health that extend beyond the gut.
The gut microbiome is altered in many diseases, but its exact role in disease development is often difficult to determine. Recent studies suggest that the gut bacteria can even affect diseases outside the intestinal tract, by altering the gut barrier. In healthy humans, the intestinal lining is a selective barrier that allows beneficial substances like nutrients and vitamins to pass from the gut into the bloodstream while keeping out harmful substances like toxins. If the intestinal lining is damaged, these harmful substances may enter the bloodstream and damage distant organs.
Two diseases where patients have an impaired gut barrier are chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD). In CKD, kidney function gradually declines until the patient needs dialysis and eventually a kidney transplant. In NAFLD, the liver accumulates fat cells, which for some people leads to severe liver damage that requires a liver transplantation. Although studies suggest that the microbiome can affect the gut barrier, it has not yet been proven that gut bacteria directly impair the gut barrier in CKD and NAFLD.
Our project will test whether the damaged gut barrier seen in CKD and NAFLD is caused by changes in the gut microbiome. We will identify potentially important bacterial species by determining which bacteria show similar changes in both CKD and NAFLD. This could lead to the development of new therapeutic strategies that target gut bacteria rather than the diseased organs. New therapies that decrease the need for dialysis and organ transplantation would greatly improve quality of life while reducing costs for the Canadian healthcare system.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stintzi, Alain; Burns, Kevin D; Fergusson, Dean A; Figeys, Daniel; Jimenez, Carolina; Lalu, Manoj M; Lavallée-Adam, Mathieu; Levy, Emile; Mack, David R
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $25,000~ $0~